IP Library Granted Patent US 9,526,880
Granted Patent B2
US 9,526,880 · App. 14/201,630 · Granted Dec 27, 2016

3-dimensional large capacity cell encapsulation device assembly

Inventors: Vincent So (San Diego, CA); Laura Martinson (San Diego, CA); Chad Green (San Diego, CA); Michael Scott (San Diego, CA); Mario Zamarripa (San Diego, CA)
Assignee: VIACYTE, INC.
A61M31/002A61F2/022A61M2202/09A61M2205/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,526,880
App. No.
14/201,630
Granted
Dec 27, 2016
Kind
B2
Abstract

Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.

Claims (17)

1. A cell encapsulating assembly, said assembly comprising at least two cell chambers and a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees.

2. The assembly of claim 1 , wherein the assembly comprises a semi-permeable membrane.

3. The assembly of claim 1 , wherein the assembly comprises at least three, four, five, six, seven, eight or more cell chambers.

4. The assembly of claim 1 , further comprising at least one loading port.

5. The assembly of claim 1 , further comprising definitive endoderm-lineage cells.

6. The assembly of claim 1 , further comprising human immature beta cells.

7. The assembly of claim 1 , further comprising a cell chamber matrix having a plurality of interconnected cavities or pores to disperse the living cells and to improve oxygen distribution inside the cell chamber.

8. The assembly of claim 7 , wherein the interconnected cavities have different cavity dimensions.

9. The assembly of claim 7 , wherein the matrix is polydimethylsiloxane (PDMS), polydimethylsiloxane mono acrylate, and polydimethylsiloxane monomethacrylate.

10. The assembly of claim 7 , wherein the matrix is a silicone elastomer.

11. The assembly of claim 7 , wherein the matrix is a polydimethylsiloxane (PDMS).

12. The assembly of claim 1 , wherein the cell chambers are separated by about 20 degrees.

13. The assembly of claim 1 , wherein the cell chambers are separated by about 40 degrees.

14. A encapsulating assembly, said assembly comprising at least two cell chambers, a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees, further comprising human endocrine precursor cells.

15. The assembly of claim 14 , further comprising human pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells.

16. The assembly of claim 1 , further comprising a partition seal within the cell chamber.

17. A cell encapsulating assembly, said assembly comprising at least two cell chambers and a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees and further comprising pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2016
From: ZAMARRIPA, MARIO
To: VIACYTE, INC.
Reel/Frame 040044/0056 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2014
From: SO, VINCENT; GREEN, CHAD; MARTINSON, LAURA; SCOTT, MICHAEL
To: VIACYTE, INC.
Reel/Frame 033517/0898 →
Continuity (2)
Provisional Application 61774443 · Mar 7, 2013
Related Publication 20140257515A1 · Sep 11, 2014